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Abstract We investigated the expression of the yeast Kex2 
family endoproteases furin and PACE4, and brain natriuretic 
peptide (BNP) in the atrium and ventricle after infarction as well 
as the conversion of the BNP precursor γΒΝΡ to BNP-45. In a 
rat heart failure model, plasma BNP rose in two phases - first at 
day 3, and again at day 14. BNP mRNA, as measured by 
Northern blot analysis, increased strongly at day 3, then at days 
14 and 28 less strongly in the atrium, and in the ventricle it 
increased weakly at day 3, then strongly at days 14 and 28. Furin 
mRNA showed the same pattern of expression as that of BNP 
message, whereas PACE4 message stayed unchanged after the 
infarction. Both furin and BNP were immunostained in the 
myocardium adjacent to the infarcted tissue. We suggest that 
after myocardial infarction, furin is co-expressed with BNP in 
both the atrium and ventricle, and that furin may be responsible 
for the conversion of 7BNP to BNP-45. 
Key words: Brain natriuretic peptide; Furin; PACE4; 
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1. Introduction 
Atrial natriuretic peptide (ANP) and brain natriuretic pep-
tide (BNP) regulate blood pressure, diuresis, natriuresis, and 
dilation of vascular smooth muscles [1,2]. In congestive heart 
failure and hypertrophic cardiomyopathy, plasma levels of 
ANP and BNP rise quickly [3,4]. In those conditions BNP 
is extensively produced in the atrium and ventricle, whereas 
ANP is produced mostly in the atrium, and in severe cases in 
the ventricle - where ANP is not expressed in a normal state 
[5]. Plasma ANP declines gradually with the recovery of car-
diac function while plasma BNP continues elevated for a 
while [3,6]. To close scrutiny, plasma BNP increases rapidly 
after the infarction, decreases gradually, then increases after 
2 weeks in patients with myocardial infarction [3]. A similar 
diphasic rise in BNP was also observed in rats with congestive 
heart failure caused by experimental arteriovenous fistula be-
tween the infrarenal aorta and the vena cava, although the 
first rise peaked at day 2 and the second rise at day 8 after the 
operation [7]. Since the rise of BNP levels is more marked and 
longer than those of ANP in congestive heart failure and 
hypertrophic cardiomyopathy, BNP is thought to be a more 
valuable marker for those disorders than ANP [3,6]. 
BNP is synthesized from its precursor, γΒΝΡ, primarily in 
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the atrium and ventricle, although BNP was initially isolated 
from the porcine brain [8,9]. γΒΝΡ and its processed form, 
positioned at the carboxy-terminal side of γΒΝΡ, exhibit dif-
ferent sizes in different species [9]. γΒΝΡ consists of 108 amino 
acids in humans, 105 in pigs, and 95 in rats. This precursor is 
converted to 32 amino acid BNP in humans, 26 and 32 amino 
acid BNPs in pigs, and 45 amino acid BNP in rats. The cleav-
age site of BNP in these species consists of a consensus 
amino acid sequence of -Arg-X-X-Arg J, Ser- [9]. The Arg-X-
X-Arg (RXXR) motif is found also in other cardiovascular 
peptide precursors including the amino-terminus of BNP and 
C-type natriuretic peptide (CNP) [9,10], and both amino- and 
carboxyl-termini of adrenomedullin [11] and big endothelin 
[12]. This motif is cleaved by yeast Kex2 family endopro-
teases, furin and PACE4 [13,14]. Furin is thought to have 
much wider substrate specificity than PACE4 [13,14]. These 
two endoproteases are reported to be localized in cardiocytes 
[15]. Especially PACE4 is abundant in both the atrial and 
ventricular cardiocytes. Thus, furin and/or PACE4 are the 
most plausible endoprotease candidates for the conversion 
of γΒΝΡ to BNP. If furin and/or PACE4 function as a proc-
essing endoprotease for BNP, we thought these enzymes 
might follow the expression of BNP in the atrium and ven-
tricle after infarction. 
In this paper we demonstrate that furin was co-expressed 
with BNP in both atrium and ventricle after myocardial in-
farction by the ligation of coronary arteries in rats. In con-
trast, PACE4 stayed unchanged in infarcted atrium and ven-
tricle. Furin and BNP were immunostained in the same region 
close to the infarcted tissues. We suggest that furin plays an 
essential role in the processing of γΒΝΡ to BNP. 
2. Materials and methods 
2.1. Surgical procedures 
Male Wistar rats weighing approximately 250 g were purchased 
from the Oriental Yeast Co., Tokyo. The left anterior descending 
coronary artery was ligated to cause left ventricular infarction as 
described previously [16]. Briefly, rats were anesthetized with diethyl 
ether. After left thoracotomy the heart was everted, and the left cor-
onary artery was then ligated. Sham operations were performed using 
an identical procedure without ligation of the coronary artery. The 
rats with coronary artery ligation (MI rats) and those with sham 
operations were killed with a lethal injection of sodium pentobarbital 
on day 1, 3, 7, 10, 14, or 28 after the operation (n = 3-7 on each 
indicated day). In most MI rats, the infarcted area occupied 30-
50% of the ventricular wall as determined by histological examination. 
After death, the heart was removed and the atrium and left ventricle 
were dissected out. The weight of each tissue was as follows: sham-
operated atrium 0.35-0.41 g, sham-operated left ventricle 0.55-0.67 g, 
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MI rat atrium 0.41-0.60 g, MI rat left ventricle 0.61-0.80 g. In MI 
rats, the weight of each tissue increased over a period of days after the 
operation. The tissues were stored at —80°C until use. 
2.2. Radioimmunoassay for BNP 
RIA was carried out using a radioimmunoassay (RIA) kit for rat (r) 
BNP-45 (RIK 9085, Peninsula Laboratories, Belmont, CA, USA) [17]. 
The antibody was added to test samples and incubated for 16-24 h at 
4°C. 125I-labeled BNP (10000-15000 cpm) was then added, mixed, 
and incubated again at 4°C for 16-24 h. The second antibody (goat 
anti-rabbit immunoglobulin G mixed with normal goat serum) was 
added to the above mixture, then incubated at room temperature for 
90 min. RIA buffer supplied with the kit was added, and the samples 
were vortexed and centrifuged for 20 min at 3000 rpm. The super-
natant was removed and the radioactivity in the pellets was counted in 
a gamma counter. 
2.3. Northern blot analysis 
Total RNA isolation from the atrium and left ventricle and North-
ern blotting were performed as described previously [18]. After trans-
ferring RNA onto a nylon membrane (Hybond-N, Amersham Japan, 
Tokyo), hybridization was carried out in a solution consisting of 
5XSSPE (20XSSPE = 3.6 M NaCl, 200 mM NaH2P04 , 20 mM 
EDTA, pH 7.4), lOxDenhardt's reagent (0.2% Ficoll, 0.2% polyvin-
ylpyrrolidone, 0.2% BSA), 50% formamide, 1.4% sodium dodecyl 
sulfate (SDS), and 0.1 mg/ml salmon sperm DNA with either a 32P-
labeled rat BNP cDNA fragment (628 bp) [19], mouse furin cDNA 
fragment (924 bp) [20], or rat PACE4 cDNA fragment (797 bp) [14]. 
After hybridization, the membrane was washed with 0.1XSSC and 
0.1% SDS at room temperature for 5 min two to three times, then at 
55°C for 30 min. The membrane was exposed to an X-ray film (Ko-
dak, XAR 5) with an intensifying screen at —80°C. 
2.4. Enzyme assay 
Processing enzyme activities were measured for the homogenate of 
atrium at day 3 and ventricle at day 14 after the operation using the 
three substrates pyroglutamyl-arginyl-threonyl-lysyl-arginyl methyl-
coumarylamide (pyr-Arg-Thr-Lys-Arg-MCA), i-butyloxycarbonyl-
alanyl-glycyl-prolyl-argininyl methylcoumarylamide (boc-Ala-Gly-
Pro-Arg-MCA), and ?-butyloxycarbonyl-glycyl-lysyl-argininyl methyl-
coumarylamide (boc-Gly-Lys-Arg-MCA) (Peptide Institute, Inc., Osa-
ka, Japan). The substrates pyr-Arg-Thr-Lys-Arg-MCA, boc-Ala-Gly-
Pro-Arg-MCA, and boc-Gly-Lys-Arg-MCA are designed to assess 
furin, rat ANP precursor processing enzyme, and paired basic residue 
cleavage enzyme, respectively. The enzyme activity was measured by 
the production of liberated fluorescent aminomethylcoumarin (AMC) 
from the carboxyl-terminus of a synthetic peptide substrate [21]. En-
zyme source was prepared by sonicating and homogenizing the myo-
cardial tissues in PBS containing 1 mM CaCl2 and 2% n-octylgluco-
side, a detergent. To the homogenate of 0.20 ml, 20 nmol of a 
synthetic substrate was added to make a total volume of 0.25 ml, 
containing 1 mM CaCl2, 50 mM HEPES (pH 7.3), and 1% κ-octyl-
glucoside. The enzyme reaction was performed at 37°C for 2 h, then 
2.0 ml of 5 mM EDTA was added to stop the reaction. The liberated 
AMC was fluorometrically measured with excitation at 380 nm and 
emission at 460 nm. Protein concentration was measured using the 
Bradford method (Bio-Rad, Richmond, CA, USA) using bovine ser-
um albumin as a standard. 
2.5. Tissue extraction 
For extracting BNP from the tissues, the dissected samples were 
boiled for 10 min in 10 volumes of water to inactivate intrinsic pro-
teases [17]. After cooling, glacial acetic acid was added to a final 
concentration of 1 M, and the resultant mixture was homogenized 
for 4 min with a Polytron homogenizer. The supernatants, obtained 
after centrifugation at 8000 rpm for 20 min, were each diluted two-
fold with water and loaded onto a Sep-pak C18 cartridge (Millipore, 
Milfold, MA, USA). After washing the cartridge with 0.5 M acetic 
acid, adsorbed peptides were eluted with 60% acetonitrile containing 
0.1% trifluoroacetic acid (TFA). Each eluate was evaporated under 
vacuum prior to lyophihzation. Lyophilized samples were dissolved in 
0.1% TFA and applied to a reverse-phase high performance liquid 
chromatography (HPLC). HPLC analysis was carried out using a 
Nucleosil 10C18 column (4.6X 150 mm, Chemco Pak, Osaka, Japan). 
The column was equilibrated with 0.1% TFA, and eluted with a linear 
gradient of 0-60% acetonitrile in 0.1% TFA at a flow rate of 1 ml/min. 
Aliquots of all fractions were subjected to RIA for BNP. 
For extracting BNP from blood, a heparinized syringe was used to 
collect blood samples. The sample was transferred to a chilled test 
tube containing EDTA (7.5 mg/5 ml), centrifuged (3000 rpm for 10 
min at 4°C), and the plasma was stored at —80°C. BNP was extracted 
according to the method previously reported [22]. Briefly, 1 ml of 
plasma samples were acidified with 1 ml of 0.1% TFA. After centri-
fugation, the solution was passed through a Sep-pak C18 cartridge. 
After the cartridge was washed with 0.1%) TFA, the absorbed peptides 
were eluted with 60% acetonitrile in 0.1% TFA. After evaporating 
each eluate via a centrifugal evaporator, the dried residue was dis-
solved in an assay buffer for RIA. 
2.6. Immunocytochemistry 
For furin immunostaining, the ventricular myocardium, including 
infarcted tissue, was fixed with 4.0% paraformaldehyde in 0.1 M 
phosphate buffer, pH 7.4, overnight at 4°C, then transferred sequen-
tially to 10-20% sucrose in the phosphate buffer overnight at 4°C. The 
myocardium was cryoprotected with Tissue-Tek OCT. Radial sections 
of the myocardium were cut 3 μpiι thick at —20°C using a Jung Cryo-
cut 3000 (Leica Instruments GmbH, Germany). Sections were 
mounted on gelatin-coated slides and dried at 37°C. The fixed samples 
were immunostained with first antibody anti-furin serum raised in a 
rabbit, and second antibody indodicarbocyanide (Cy3)-conjugated af-
finity-purified donkey anti-rabbit IgG (Jackson ImmunoResearch, 
West Grove, PA, USA), as described before [18]. 
For BNP immunostaining, the ventricular myocardium was fixed 
with formalin, then embedded in paraffin and sectioned 4 μιη thick. 
The sections were deparaffinized and incubated for 30 min in a solu-
tion of methanol containing 0.5% hydrogen peroxide to denature en-
dogenous peroxidase. The sections were incubated with first antibody 
anti-BNP serum raised in a rat, and second antibody horseradish 
peroxidase-conjugated affinity-purified donkey anti-rat IgG (Jackson 
ImmunoResearch). The peroxidase reaction was carried out using 
3,3'-diaminobenzidine tetrahydrochloride (Dojindo Ltd., Kumamoto, 
Japan) and 0.005% hydrogen peroxide. After the reaction samples 
were stained with hematoxylin to visualize nuclei. 
3. Results 
3.1. Plasma BNP after ligation of the left coronary artery 
To examine the possibility that the pro-protein processing 
endoproteases furin and/or PACE4 are responsible for the 
cleavage of γΒΝΡ, we generated experimental myocardial in-
farction by ligating the left anterior descending coronary ar-
tery in rats. The rate of successful operation was approxi-
mately 70-80% in the ligation of the coronary artery, and 
100% in the sham operation. Rats in which 30-50% of the 
left ventricular myocardium was infarcted were used in this 
1 3 7 10 14 28 
days 
Fig. 1. Serial changes in plasma immunoreactive BNP over 4 weeks 
in MI and sham-operated rats. MI rats were produced by ligating 
the descending left coronary artery. Filled bars indicate plasma 
BNP in MI rats. Open bars indicate plasma BNP in the sham-oper-
ated rats. Bars represent the mean ± S.E.M. 
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a little higher at day 3 than at days 14 and 28, whereas the 
expression in the MI ventricle was more striking at days 14 
and 28 than at day 3. Thus, elevated levels of plasma BNP in 
MI rats on days 3, 14, and 28 reflected the result of the rise of 
BNP expression in both atrium and left ventricle. 
We next investigated furin and PACE4 expression in corre-
lation with BNP expression. In sham-operated rats, furin was 
expressed at low levels in both the atrium and left ventricle. In 
MI rats furin was highly expressed in both the atrium and 
ventricle. Atrial furin expression was higher at days 3, 14, and 
28, but decreased to the control level at day 7 (Fig. 2A). The 
furin expression in the MI ventricle was also strikingly high at 
days 3, 14, and 28, but the level was much higher at days 14 
and 28 than at day 3 (Fig. 2B). The furin mRNA level at day 
7 was diminished to a level similar to day 1. The profile of 
furin expression correlated strongly with that of BNP both in 
the atrium and in the ventricle. 
On the other hand, expression of PACE4 was low in both 
the atrium and left ventricle of sham-operated rats. In the MI 
atrium PACE4 mRNA stayed constant at the level of sham-
operated atrium even at days 3, 14 and 28, when both BNP 
and furin expression were markedly elevated. In the MI ven-
tricle the mRNA was a little elevated at days 7 and 14. How-
ever, compared with the striking up-and-down movement of 
BNP and furin, PACE4 expression was rather motionless in 
both the atrium and ventricle of MI rats. 
Fig. 2. Northern blot analysis of BNP, furin, and PACE4 mRNAs 
in the atrium (A) and left ventricle (B). In sham-operated rats total 
RNA was isolated from the atrium and left ventricle at days 3 and 
14 after the operation. In MI rats total RNA was isolated at days 
1, 3, 7, 14, and 28. Upper panel: BNP mRNA in the atrium (A) 
and left ventricle (B) of sham-operated and MI rats. Middle panel: 
furin mRNA in the atrium (A) and left ventricle (B) of sham-oper-
ated and MI rats. Lower panel: PACE4 mRNA in the atrium (A) 
and left ventricle (B) of sham-operated and MI rats. Ribosomal 
RNAs are indicated as 28S and 18S. 
3.3. Furin-like protease activities in the atrium and ventricle 
Since expression of furin and BNP was highly correlated in 
the atrium and ventricle of MI rats, we assayed the proteolytic 
activities contained in the atrial and ventricular lysate. We 
used three enzyme substrates: boc-Ala-Gly-Pro-Arg-MCA, a 
substrate for rat ANP precursor processing enzyme; boc-Gly-
Lys-Arg-MCA, a substrate for dibasic site cleavage enzyme; 
and pyr-Arg-Thr-Lys-Arg-MCA, a substrate for furin. In the 
sham-operated atrium and ventricle, proteolytic activity to the 
experiment. Serial changes in plasma immunoreactive BNP 
(irBNP) over 4 weeks after the operation are shown in Fig. 
1. Plasma BNP increased at day 3 and fell by day 7, then 
began to increase again until day 14. Increased levels of plas-
ma BNP continued as late as day 28. In sham-operated rats, 
plasma BNP stayed at low levels. BNP levels were 4.5-fold 
higher at day 3 and 2.0-fold higher at day 14 in the MI rats 
than in sham-operated rats. 
3.2. Northern blot analysis of BNP, furin, and PACE4 
Since plasma BNP was elevated at days 3 and 14 in MI rats, 
we examined BNP expression in the atrium and left ventricle 
by Northern blotting (Fig. 2A,B). In sham-operated rats, 
BNP mRNA stayed consistently faint at days 3 and 14 in 
the atrium as well as in the left ventricle. Likewise, in MI 
rats BNP mRNA was faint at day 1 in both atrium and left 
ventricle. In contrast, in the atrium of MI rats BNP expres-
sion was markedly elevated at days 3, 14, and 28. However, it 
was distinctly decreased at day 7. In the left ventricle of MI 
rats the expression of BNP message was similarly elevated at 
days 3, 14, and 28, and it was higher at days 14 and 28 than at 
day 3 (Fig. 2A,B). At day 7 BNP mRNA decreased like in the 
MI atrium. Thus, in both MI atrium and ventricle BNP 
mRNA rises at day 3, decreases at day 7, then increases again 
at days 14 and 28. The BNP expression in the MI atrium was 
Sham Sham 
Fig. 3. Proteolytic activities in the extracts from the atrium and ven-
tricle of sham-operated and MI rats. Proteolytic activity of atrial 
and ventricular lysates were measured to the three synthetic sub-
strates: boc-Ala-Gly-Pro-Arg-MCA, boc-Gly-Lys-Arg-MCA, and 
pyr-Arg-Thr-Lys-Arg-MCA. The activity was assayed in the reac-
tion containing 1 mM CaCl2 at pH 7. Open bar, proteolytic activity 
for the ANP processing enzyme substrate boc-Ala-Gly-Pro-Arg-
MCA; hatched bar, proteolytic activitiy for the dibasic site cleavage 
enzyme substrate boc-Gly-Lys-Arg-MCA; filled bar, proteolytic ac-
tivity for the furin substrate pyr-Arg-Thr-Lys-Arg-MCA. 
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Fig. 4. Immunocytochemical staining of furin and BNP in the ventricle of sham-operated and MI rats at day 14. A and B: Furin staining. 
Ventricles from a sham-operated rat (A) and a MI rat (B) were stained with rabbit antibody to furin and Cy3-labeled donkey anti-rabbit IgG 
(red). Healthy myocardium appears red, nuclei are stained blue with 4,6-diamidino-2-phenylindole, and furin is stained orange (indicated by ar-
rows). C and D: BNP staining. Ventricles from a sham-operated rat (C) and a MI rat (D) were incubated with rat antibody to BNP and 
horseradish peroxidase-labeled donkey anti-rat IgG. Preoxidase reaction was performed with 3,3'-diaminobenzidine and hydrogen peroxide to 
produce light-brown staining. 
dibasic substrate was low compared with that to the other two 
substrates. Between the two, furin-type enzyme activity was a 
little higher than ANP-processing-type enzyme activity. In the 
MI atrial and ventricular lysates proteolytic activity to any of 
the three substrates was increased extensively. Especially fur-
in-like activity was most enhanced compared with monobasic 
and dibasic site cleavage enzymes (Fig. 3). Thus, enhanced 
furin mRNA expression in the MI atrium and ventricle re-
flected the increase of furin-like proteolytic activity. 
3.4. Immunocytochemical staining of furin and BNP 
A high level of furin and BNP expression was noted in the 
left ventricle at day 14 in MI rats. Histological observation 
showed that the myocardium of MI rats exhibited character-
istics typical of infarction: on a macroscopic scale, there was 
fibrosis and thinning of the ventricular wall, and on a micro-
scopic scale, there was an absence of the nucleus, infiltration 
of inflammatory cells, and hyperplasia of fibroblasts. In the 
ventricle of MI rats stained with Cy3-conjugated antibody, 
the myocardium was observed to be red, and the infarcted 
tissue appeared as a dark shadow with light blue-stained nu-
clei (Fig. 4B). Furin was stained scatteringly as orange-colored 
spots (indicated by arrows) in red-colored myocardium. These 
orange-colored spots were not observed in the control ventric-
ular tissue (Fig. 4A). The furin-positive myocardium was lo-
cated close to the infarcted area. 
BNP was also localized in the same region adjacent to the 
infarcted tissue (Fig. 4D). Since ventricular myocytes do not 
possess secretory granules, BNP was stained light-brown in 
the whole cytoplasm. This light-brown staining was not ob-
served in the control ventricular tissues (Fig. 4C). This finding 
is similar to the previous report that BNP immunostaining 
was localized in the cardiocytes surrounding the infarcts and 
in the surviving cardiocytes in the infarcts [4]. Thus, co-ele-
vated furin and BNP were shown to be localized in the same 
region. 
3.5. Molecular forms of BNP in the atrium and left ventricle 
If furin converts γΒΝΡ to BNP-45, a higher level of furin 
expression may result in the increased production of BNP-45. 
To investigate this possibility we analyzed irBNP from the 
atrium and ventricle, differentiating the two species by the 
fact that BNP-45 elutes first, γΒΝΡ last, from an HPLC col-
umn. The ratio of γΒΝΡ to BNP-45 in the normal atrium was 
approximately 1:2, whereas that in the atrium of MI rats was 
1:3.4 at day 3 and 1:3.5 at day 14 (Fig. 5A). Likewise, the 
ratio of γΒΝΡ to BNP-45 in the normal ventricle was approxi-
mately 1:1, whereas this ratio became 1:3 at day 3 and 1:3.5 
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Fig. 5. Molecular forms of BNP in the atrium and left ventricle of 
control and MI rats. Immunoreactive BNP was separated into 
γΒΝΡ and BNP-45 via reverse phase HPLC. A: BNP in the atrium; 
top, control (without MI operation); middle, at day 3; bottom, at 
day 14. B: BNP in the ventricle; top, control (without MI opera-
tion); middle, at day 3; bottom, at day 14. In each assay three to 
five samples were combined for BNP extraction. Similar elution pro-
files were obtained in at least three other experiments. 
at day 14 in the MI ventricles (Fig. 5B). Thus, the ratio of 
γΒΝΡ to BNP-45 fell in both the atrium and ventricle of MI 
rats, indicating that the increase in plasma BNP-45 after myo-
cardial infarction likely derives from increased processing of 
γΒΝΡ in the myocardium. 
4. Discussion 
The present results indicate that plasma BNP in MI rats 
rose to a high level at day 3 and again at days 14-28 after 
ligating the descending left coronary artery (Fig. 1), and that 
both BNP and furin mRNAs were highly expressed in the 
atrial and ventricular myocardia at day 3 and again at days 
14-28 (Fig. 2). The expression level of BNP or furin in the 
atrium was similar at days 3, 14, and 28, whereas the level in 
the ventricle was higher at days 14 and 28 than at day 3. 
Thus, BNP and furin mRNAs were highly expressed earlier 
in the atrium than in the ventricle. The time shift of each 
expression may be explained by the difference between the 
pressure loads in the atrium and the ventricle [23]. Since the 
atrial wall is thinner than that of the ventricle, increasing 
pressure load may initially stretch the atrial wall more 
strongly than the ventricular wall, so that the first rise of 
plasma BNP at day 3 contributes considerably to high BNP 
expression in the atrium. On the other hand, since the mass of 
ventricular tissue is larger than that of the atrium, and the 
expression of BNP mRNA is similar in the two tissues in a 
normal state [6,10], BNP produced from the ventricle will 
contribute much more to the rise in plasma BNP than BNP 
from the atrium at days 14-28. 
Furin mRNA rose simultaneously with that of BNP in the 
atrium and ventricle of MI rats. This, together with the fact 
that rat, pig, and human gBNPs contain furin cleavage sites 
RXXR at the amino-termini of their respective BNP mole-
cules, suggests that furin may be the physiologic generator 
of BNP from γΒΝΡ [9,24]. If γΒΝΡ is a substrate for furin, 
BNP and furin should be expressed in the same cells. 
Although we attempted to show this co-localization in the 
same cells, we could not demonstrate it because of a technical 
immunostaining problem. However, immunostaining study 
demonstrated that BNP and furin were distributed in the 
same myocardial region adjacent to the infarcted tissue (Fig. 
4). The expression of PACE4 stayed rather constant com-
pared with a dramatic elevation of furin with BNP both in 
the atrium and in the ventricle after experimental myocardial 
infarction. Thus, we think furin but not PACE4 is a primary 
endoprotease for the conversion of γΒΝΡ to BNP-45 at the 
RXXR motif, although PACE4 is produced at a high level in 
the atrial and ventricular cardiocytes in normal condition [15]. 
Mononuclear inflammatory cells accumulated in the in-
farcted tissue. Cardiocytes surviving the infarct are likely ex-
posed to a variety of cytokines and growth factors, some of 
which are probably produced from these mononuclear cells 
[25]. Along with these humoral stimulants, cardiocytes are 
also affected by the stretch force and pressure load resulting 
in the rapid secretion of BNP [4,26]. Thus, the expression of 
both BNP and furin is regulated by these physical and hu-
moral stimulants. Recently we found that mechanical stretch 
of cultured cardiocytes induced extensive expression of both 
BNP and furin (Y. Sawada et a l , unpublished data). 
In atrial cardiocytes BNP is stored in the secretory granules 
and secreted through a pathway regulated by extracellular 
signals [1,2]. In general, pro-peptide hormones are processed 
by prohormone convertases such as PC2 or PC3 in the freshly 
formed immature secretory granules [27]. However, atrial 
granules do not contain such prohormone convertases [15]. 
ANP is contained as a precursor in the atrial granules and 
processed when it is secreted [28]. A processing enzyme for 
ANP appears to be granule membrane-associated. BNP pre-
cursor may be converted to BNP-45 by furin at the TGN, 
then stored in the secretory granules in the atrium. In con-
trast, ventricular cardiocytes do not possess secretory gran-
ules, and secrete BNP into the blood stream through a con-
stitutive pathway without retention in the cytoplasm. The 
conversion to BNP-45 appears to be more efficient in the 
atrium than in the ventricle because irBNP extracted from 
the atrium showed approximately a 2:1 proportion of BNP-
45 to γΒΝΡ whereas irBNP from the ventricle had almost a 
1:1 proportion (Fig. 5). In the MI atrium and ventricle the 
proportion of BNP-45 to γΒΝΡ was increased over 3:1 pre-
sumably due to the increase of furin expression. 
In the infarcted myocardium a number of genes are ex-
pressed in a cascade fashion, and cardiocytes surviving the 
infarct undergo hypertrophic growth in an autocrine, juxta-
crine, and/or paracrine fashion [29,30]. We suggest that the 
genes for both furin and BNP are among the genes induced 
early after the myocardial infarction, and BNP converted by 
furin compensates for cardiac overload by inducing dilation of 
vascular smooth muscles, natriuresis, and decrease of blood 
pressure. 
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